Vanda Pharmaceuticals Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $VNDA in the last 30 days.
See all $VNDA insider activity →Vanda Pharmaceuticals (VNDA) stock rose 12% in after-hours trading to $5.63 after reporting positive phase III results for its Hetlioz treatment in delayed sleep-wake phase disorder. The trial met its primary endpoint, and the company plans to discuss the data with the FDA. If approved, Hetlioz would be the first FDA-approved medicine for this condition.
Vanda Pharmaceuticals (VNDA) reported positive Phase III results for HETLIOZ® in treating Delayed Sleep-Wake Phase Disorder. The study showed a 37.1-minute earlier sleep onset vs. placebo. Vanda plans to submit an sNDA for this new indication, aiming to make HETLIOZ® the first FDA-approved treatment for the disorder.
Vanda Pharmaceuticals Inc. [VNDA] launched two new drugs, NEREUS and BYSANTI. BYSANTI's launch and a switch strategy from Fanapt are expected to drive near-term revenue. The company aims for $750 million in psychiatry revenue by 2030, supported by phase III readouts and product diversification, according to its 12th Annual Cantor Fitzgerald Global Healthcare Conference.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning VNDA (Vanda Pharmaceuticals Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent VNDA coverage spans regulation, technology and financial news.
Positive trial data likely fuels buying pressure as investors anticipate FDA approval.
Positive pivotal data suggest a potential label expansion, likely boosting the stock.
Positive product approvals and launch could boost near-term sales and drive stock upside.
The announced BYSANTI launch and extended clinical timelines provide fresh growth catalysts, potentially supporting the stock price.
Regulatory approval adds a new product line.
AlphAI scores every news story that mentions VNDA with an AI model for sentiment and relevance, and aggregates insider trades from Vanda Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vanda Pharmaceuticals (VNDA) stock rose 12% in after-hours trading to $5.63 after reporting positive phase III results for its Hetlioz treatment in delayed sleep-wake phase disorder. The trial met its primary endpoint, and the company plans to discuss the data with the FDA. If approved, Hetlioz would be the first FDA-approved medicine for this condition.
2 min readVanda Pharmaceuticals (VNDA) reported positive Phase III results for HETLIOZ® in treating Delayed Sleep-Wake Phase Disorder. The study showed a 37.1-minute earlier sleep onset vs. placebo. Vanda plans to submit an sNDA for this new indication, aiming to make HETLIOZ® the first FDA-approved treatment for the disorder.
3 min readVanda Pharmaceuticals Inc. [VNDA] launched two new drugs, NEREUS and BYSANTI. BYSANTI's launch and a switch strategy from Fanapt are expected to drive near-term revenue. The company aims for $750 million in psychiatry revenue by 2030, supported by phase III readouts and product diversification, according to its 12th Annual Cantor Fitzgerald Global Healthcare Conference.
1 min readVanda Pharmaceuticals (VNDA) outlined its growth plans at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, targeting $750M in psychiatry revenue by 2030. The company expects BYSANTI, approved for bipolar disorder and schizophrenia, to be a key catalyst with a favorable pricing structure. VNDA also highlighted its pipeline, including NEREUS for motion sickness and potential GLP-1-related nausea and vomiting. Fanapt, a current growth driver, has a 30% year-over-year growth rate. The
3 min readU.S. stock futures fell early Monday due to tariff uncertainty and Iran tensions. Nasdaq, S&P 500, and Dow futures declined 0.5%-0.6%. Nvidia's earnings, Netflix's board controversy, and Honeywell's acquisition are in focus. Precious metals rose, with gold above $5,100 and silver near $88/oz.
2 min readVanda Pharmaceuticals (VNDA) announced FDA acceptance of its Biologics License Application for Imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The company reported positive results from clinical trials, with over 50% of patients achieving clear or almost clear skin. VNDA shares rose nearly 5% in pre-market trading.
1 min readVanda Pharmaceuticals (VNDA) received Orphan Designation from the European Commission for imsidolimab, a treatment for Generalized Pustular Psoriasis (GPP). The drug also has similar designations in the US and Japan. The FDA is reviewing the Biologics License Application with a target action date of December 12, 2026.
2 min readMillennium Management LLC and related entities report a 5.6% passive stake in Vanda Pharmaceuticals (VNDA), owning 3.38M shares. They share voting and disposal power but deny sole beneficial ownership. The filing is made under a joint agreement.
1 min readVanda Pharmaceuticals (VNDA) shares surged 38% after the FDA approved Bysanti for treating bipolar I disorder and schizophrenia. The drug is expected to launch in Q3 2026. VNDA also has another drug, Nereus, approved for motion sickness, but faced rejection for Hetlioz in treating jet lag. Retail sentiment on Stocktwits turned 'extremely bullish'.
2 min readVanda Pharmaceuticals (VNDA) stock surged 40% after FDA approved its Bysanti tablets for bipolar I disorder and schizophrenia. Analysts' price targets range from $7.5 to $22, with an average of $13.63. The company expects Bysanti to launch in Q3 2026 and has other drugs in development.
4 min read
